LARVOL
@Larvol
AI-Powered #Data Solutions & Services for the #Biotech & #Pharmaceutical Industry. We're a team of over 150 #DigitalNomads 🌎🐯
How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch…
📣 𝕏 Post of the Day (July 23, 2025) Dr. Vincent Rajkumar, MD (@VincentRK) shares a key update on AQUILA: The European Commission (EC) has approved a new indication for DARZALEX ® (daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment of adult patients…
Titles of poster and oral presentations for the upcoming World Conference on Lung Cancer 🫁 (@IASLC-WCLC 2025), to be held in Barcelona, Spain from September 6–9, 2025, have been released. 🔗 Follow us for latest clinical trial and insights from the world of oncology:…
European Commission approves Darzalex Faspro® (daratumumab and hyaluronidase-fihj) as the first licensed treatment for patients with high-risk smouldering multiple myeloma globenewswire.com/news-release/2… Learn more about AQUILA study (NCT03301220) 👉 clin.larvol.com/trial-detail/N… #LARVOL…
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant. globenewswire.com/news-release/2… Learn more about TRIANGLE (NCT02858258) 👉…
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation. globenewswire.com/news-release/2… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights #BreastCancer #INAVO120 Learn more…
If you're a practicing oncologist looking for easier access to clinical trial data and oncology insights, we’re offering complimentary access to @Larvol CLIN. To get access, email your details to [email protected]. Or comment "Oncology" and we’ll follow up with you directly.…
📣 𝕏 Post of the Day (July 21, 2025) Dr. Stephen Liu, MD (@StephenVLiu) shares a key update on FLAURA2: The addition of chemotherapy to 1L osimertinib in EGFR+ NSCLC improves overall survival. Already approved based on PFS. Awaiting OS data to compare with MARIPOSA. 🔗 Learn…
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer. Learn more about FLAURA2 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData…
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) globenewswire.com/news-release/2… Learn more 👉…
Bayer’s Nubeqa (darolutamide) receives EU approval in third indication for patients with advanced prostate cancer. bayer.com/media/en-us/ba… Learn more 👉 Phase III ARANOTE trial (NCT04736199): clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData…
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Learn more about TALAPRO-2 trial 👉 clin.larvol.com/trial-detail/N… #LARVOL…
Our abstract on Pooled Analysis in 1L HCC: Immune Checkpoint Inhibitor vs Tyrosine Kinase Inhibitor Regimens has been accepted for poster presentation at @myESMO Congress 2025 in Berlin 🇩🇪 See you there. #LARVOL #ESMO25 #Oncology #CancerResearch #CancerData #OncologyInsights |…
We benchmarked 10 AI models on their ability to identify Originators for Biosimilars. The gap in results was massive. GPT-4o was the clear winner with a 94% F1 score, delivering the best balance of precision and recall. The key insight: Some models achieved 100% precision but…
🎙️ New Podcast Collaboration: @ASCO 2025 Summary Judith Perez (@Jud_Prz) from @Larvol joins @VuMedi to share key takeaways from ASCO® 2025, focusing on BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM). #LARVOL #VuMedi #ASCO25 #CancerResearch #Oncology…
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer globenewswire.com/news-release/2… Learn more about KEYNOTE-A78 (NCT03978689) 👉…
1/ 🚨 Out Now @TheLancetOncol DREAMM-7 Update (Phase 3): Belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + Vd (DVd) in relapsed/refractory multiple myeloma after ≥1 prior line of therapy. Results are in—. 🧬🔥 #mmsm #MedEd #myeloma #MedTwitter #USMIRC…
The CHALLENGE trial (@ASCO @NEJM) revived hope for exercise in colorectal cancer debate continues. Now, a new meta-analysis shows: Consistent or increasing physical activity over adulthood cuts all-cause and CVD death risk by up to 40%. Move for your life at any age! @bmj_latest…